These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 37916986)
1. Diligent Design Enables Antibody-ASO Conjugates with Optimal Pharmacokinetic Properties. Sela T; Mansø M; Siegel M; Marban-Doran C; Ducret A; Niewöhner J; Ravn J; Martin RE; Sommer A; Lohmann S; Krippendorff BF; Ladefoged M; Indlekofer A; Quaiser T; Bueddefeld F; Koller E; Mohamed MY; Oelschlaegel T; Gothelf KV; Hofer K; Schumacher FF Bioconjug Chem; 2023 Nov; 34(11):2096-2111. PubMed ID: 37916986 [TBL] [Abstract][Full Text] [Related]
2. Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. Huggins IJ; Medina CA; Springer AD; van den Berg A; Jadhav S; Cui X; Dowdy SF Molecules; 2019 Sep; 24(18):. PubMed ID: 31509944 [TBL] [Abstract][Full Text] [Related]
3. Bioanalysis of free antisense oligonucleotide payload from antibody-oligonucleotide conjugate by hybridization LC-MS/MS. Jiang D; Li P; Yuan L Bioanalysis; 2024 Jul; ():1-10. PubMed ID: 39041663 [TBL] [Abstract][Full Text] [Related]
4. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. Monine M; Norris D; Wang Y; Nestorov I J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides. Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biophysical properties of tetravalent PEG-conjugated antisense oligonucleotide. Rahman Chowdhury T; Taufiq T; Ishida K; Ariful Islam M; Kasahara Y; Osawa T; Obika S Bioorg Med Chem; 2023 Jan; 78():117149. PubMed ID: 36587552 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice. Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955 [TBL] [Abstract][Full Text] [Related]
9. Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides. Nikan M; Tanowitz M; Dwyer CA; Jackson M; Gaus HJ; Swayze EE; Rigo F; Seth PP; Prakash TP J Med Chem; 2020 Aug; 63(15):8471-8484. PubMed ID: 32677436 [TBL] [Abstract][Full Text] [Related]
10. A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides. Linninger AA; Barua D; Hang Y; Iadevaia S; Vakilynejad M Front Physiol; 2023; 14():1130925. PubMed ID: 37334053 [TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960 [TBL] [Abstract][Full Text] [Related]
12. Synthesis of multivalent fatty acid-conjugated antisense oligonucleotides: Cell internalization, physical properties, and in vitro and in vivo activities. Tanaka Y; Tanioku Y; Nakayama T; Aso K; Yamaguchi T; Kamada H; Obika S Bioorg Med Chem; 2023 Mar; 81():117192. PubMed ID: 36780806 [TBL] [Abstract][Full Text] [Related]
13. Integrated Assessment of the Clinical Performance of GalNAc Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431 [TBL] [Abstract][Full Text] [Related]
14. PEG-modification on the endo-position of an antisense oligonucleotide increases tumor accumulation via the EPR effect. Hagiwara K; Kurihara K; Honma M; Yamamoto J; Shinohara F J Biomater Sci Polym Ed; 2018 Mar; 29(4):448-459. PubMed ID: 29318941 [TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment. Cao Y; Matsubara T; Zhao C; Gao W; Peng L; Shan J; Liu Z; Yuan F; Tang L; Li P; Guan Z; Fang Z; Lu X; Huang H; Yang Q Sci Rep; 2017 Aug; 7(1):9307. PubMed ID: 28839185 [TBL] [Abstract][Full Text] [Related]